These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21424110)

  • 1. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
    Matalon S; Rasmussen TA; Dinarello CA
    Mol Med; 2011; 17(5-6):466-72. PubMed ID: 21424110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
    Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.
    Huber K; Doyon G; Plaks J; Fyne E; Mellors JW; Sluis-Cremer N
    J Biol Chem; 2011 Jun; 286(25):22211-8. PubMed ID: 21531716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
    Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
    J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    Archin NM; Espeseth A; Parker D; Cheema M; Hazuda D; Margolis DM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):207-12. PubMed ID: 19239360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
    Matalon S; Palmer BE; Nold MF; Furlan A; Kassu A; Fossati G; Mascagni P; Dinarello CA
    J Acquir Immune Defic Syndr; 2010 May; 54(1):1-9. PubMed ID: 20300007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.
    Boateng AT; Abaidoo-Myles A; Bonney EY; Kyei GB
    AIDS Res Hum Retroviruses; 2022 Aug; 38(8):615-621. PubMed ID: 35778852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
    Manson McManamy ME; Hakre S; Verdin EM; Margolis DM
    Antivir Chem Chemother; 2014 Jan; 23(4):145-9. PubMed ID: 24318952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors in HIV.
    Wightman F; Ellenberg P; Churchill M; Lewin SR
    Immunol Cell Biol; 2012 Jan; 90(1):47-54. PubMed ID: 22083528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.